Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam in mild-to-moderate Alzheimer's disease
NCT04994483Phase 3Completed
- Sponsor
- Cassava Sciences
- Start
- Nov 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Started Nov 2021; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04994483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994483.